Neurotech Pharmaceuticals, Inc.

• Privately owned life science company
  ▪ Lowy Family Group (LFG) – 100% owners
• Focused on treating chronic eye disorders
• Products based on a robust technology platform.
  ▪ Encapsulated Cell Therapy (ECT)
• Two mid-to-late staged product opportunities in clinical development with promising human clinical data.
Neurotech Team/Collaborators

Management
- Rich Small, CEO
- Ken Mandell, MD, PhD, CMO
- Konrad Kauper, VP of Development
- Cahil McGovern, PhD, VP of Manufacturing

Board of Directors
- Jim Mazzo, Chairman
- David Fuchs, LFG
- John Fanning, LFG
- Rich Small, CEO

Key Collaborators
- Lowy Medical Research Institute (LMRI)
  Marty Friedlander, MD, President
- Jeff Goldberg, MD, PhD
  Chairman of Ophthalmology at the Byers Eye Institute at Stanford

MacTel Joint Steering Committee
- Marty Friedlander, MD
- Emily Chew, MD (NEI)
- Alan Bird, MD (Moorfields)
- Tom Hohman, PhD, Neurotech advisor
- Ken Mandell, MD, PhD
- John Fanning
- Rich Small
Intraocular implant that contains genetically engineered cells designed to release therapeutic proteins in a controlled, continuous delivery to the back of the eye.

- Safely implanted in ~ 300 patients.
- Viable *in vivo* for more than two years.
- Ability to deliver a variety of different therapeutic proteins.
**Renexus® (CNTF) – Clinical Programs**

- Renexus® releases ciliary neurotrophic factor (CNTF), a well studied neuroprotective agent shown to slow photoreceptor cell death in numerous animal models.

- Renexus® is currently being developed to treat:
  - **Macular Telangiectasia** (MacTel)
    - Currently in Phase 3
    - Program partnered with and financed by LFG
  - **Glaucoma**
    - Currently in Phase 2
    - Large market partnering opportunity
RENEXUS® MACULAR TELANGIECTASIA (MacTel)
Macular Telangiectasia (MacTel)

• Bilateral retinal disease that leads to a gradual loss of central vision.
  ▪ Onset of disease between age 40 to 60.

• Loss of photoreceptors in a well defined area of the retina. (MacTel Ellipsoid Zone)

• No current treatment available for MacTel.
Renexus® MacTel
Positive Phase 2 Clinical Results

• 67 participants (99 study eyes) multi-center, sham-controlled study. 24 month endpoints.

• Primary endpoint - Change in the MacTel Ellipsoid Zone
  ▪ Statistically significant reduction in the rate of change in the MacTel Ellipsoid Zone in the Renexus® treated eyes as compared with the sham eyes.

• Positive Secondary endpoint outcomes
  ▪ Microperimetry
  ▪ Reading Speed
  ▪ Macular thickening in treated group vs thinning in sham group.
  ▪ No difference in BCVA (safety).

• Renexxus® was well tolerated.
Renexus® MacTel
Phase 3 Program Initiated

• Two 112-patient multicenter, multinational (US/EU/AU), sham-controlled 24 month studies

• Primary endpoint
  ▪ Change in the MacTel Ellipsoid Zone area.

• Secondary endpoints
  ▪ Microperimetry
  ▪ Reading Speed
  ▪ BCVA (safety)

• Enrollment to be completed mid-2019

• Clinical results expected mid-2021
RENEXUS ® GLAUCOMA
• Loss of retinal ganglion cells (RGCs) is characteristic of the disease.
• Numerous animal studies demonstrate CNTF’s role in reducing the loss of RGCs.

**Can Renexus® treatment have a beneficial effect on glaucoma patients?**

• Renexus® is currently being tested in a 54 patient sham-controlled Phase 2 study
  ▪ Primary study endpoint - Change in Visual Fields
  ▪ Key secondary study endpoints - Change in the ganglion cell and nerve fiber layers
  ▪ Measuring effect over 12 and 24 month time points.

• Interim Phase 2 data (38 patients) promising.
  ▪ Neuroprotective effect as measured by Visual Fields seen after 12 months.
  ▪ Complete 12-month data (54 patients) expected by end of 2018
Neurotech - Summary

• Promising clinical data in two indications.
  ▪ Late stage (Phase 3) clinical program in MacTel.
  ▪ Large market partnering opportunity in Glaucoma.

• Novel platform technology (ECT).
  ▪ Deliver proteins safely over an extended period of time.
  ▪ Versatile platform can be utilized to treat other ophthalmic disorders.

• Outstanding research, clinical, management and financial support teams in place.